Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE vs TACE + SBRT in Unresectable HCC
NCT02794337Phase 3Unknown
- Sponsor
- Tata Memorial Hospital
- Start
- Dec 2014
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Tata Memorial Hospital. Primary endpoint: In-field Progression Free Survival at 24 months. Status: unknown.
Beyond the preview
Go deeper on NCT02794337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794337.